bullish
Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) - The Logic and the Outlook
270 Views11 Jan 2022 09:17
This insight compare the two leading companies in China medical beauty industry Bloomage and Imeik in terms of the difference in positioning, strategic layout, business logic, concerns and outlook.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities18 Jan 2022
- China Healthcare Weekly (Jan.14) - Impact on Dental Implant VBP, Prediction on 7th National VBP 202216 Jan 2022
- Pre-IPO Betta Pharmaceuticals - Lack of Staying Power13 Jan 2022
- Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) - The Logic and the Outlook11 Jan 2022
- Pre-IPO Imeik Technology Development (300896 CH) - Is High Profitability Sustainable?06 Sep 2021
- Imeik Technology Development (300896.CH) - The Valuation Bubble?19 Jul 2021
- Bloomage Biotechnology (688363.CH) - Opportunities Coexist with Challenges22 Apr 2021
x